Routine monitoring for de novo DSA post-transplant: "Is the juice worth the squeeze?"

What You'll Take Away from His Talk:

• Understand the natural history of de novo HLA antibody in low risk patients.
• Understand the patient phenotypes associated with de novo HLA antibodies post-transplant.
• Understand the risk factors associated with de novo HLA antibodies.

Strategic development of antihumoral therapies provides a means for achieving enhanced therapeutic results. The basic immunobiology of humora alloresponses is currently adequate to allow development of new therapies. Plasma cell targeted therapy is one example of new treatment paradigms based on known immunobiology. This talk will describe the biologic basis for plasma cell targeting in general, and for proteasome inhibition in particular.

What You'll Take Away from His Talk:

• Substantial evidence exists from basic research that plasma cell targeted therapy may provide a viable means for mitigating humoral alloresponses.
• Initial evidence from clinical experiences with proteasome inhibition indicate that proteasome inhibitor-based regimens offer therapeutic potential.
• Substantial opportunities exist for enhancing proteasome inhibitor therapy via combinatorial strategies.